Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
Cash to Debt No Debt
GNBT's Cash to Debt is ranked lower than
65% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. GNBT: No Debt )
GNBT' s 10-Year Cash to Debt Range
Min: 0.12   Max: No Debt
Current: No Debt

F-Score: 3
Z-Score: -93.88
M-Score: -3.63
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
ROA (%) -0.02
GNBT's ROA (%) is ranked lower than
65% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. GNBT: -0.02 )
GNBT' s 10-Year ROA (%) Range
Min: -180.14   Max: -0.02
Current: -0.02

-180.14
-0.02
ROC (Joel Greenblatt) (%) -15827.34
GNBT's ROC (Joel Greenblatt) (%) is ranked lower than
66% of the 1212 Companies
in the Global Biotechnology industry.

( Industry Median: -442.83 vs. GNBT: -15827.34 )
GNBT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -9777.78   Max: -335.65
Current: -15827.34

-9777.78
-335.65
EBITDA Growth (%) -100.00
GNBT's EBITDA Growth (%) is ranked lower than
114% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -4.60 vs. GNBT: -100.00 )
GNBT' s 10-Year EBITDA Growth (%) Range
Min: -100   Max: 108
Current: -100

-100
108
EPS Growth (%) -66.50
GNBT's EPS Growth (%) is ranked lower than
111% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. GNBT: -66.50 )
GNBT' s 10-Year EPS Growth (%) Range
Min: -66.5   Max: 46.3
Current: -66.5

-66.5
46.3
» GNBT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with GNBT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
EV-to-EBIT -2.62
GNBT's EV-to-EBIT is ranked lower than
61% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GNBT: -2.62 )
GNBT' s 10-Year EV-to-EBIT Range
Min: -6.7   Max: -0.2
Current: -2.62

-6.7
-0.2
Current Ratio 0.42
GNBT's Current Ratio is ranked lower than
66% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. GNBT: 0.42 )
GNBT' s 10-Year Current Ratio Range
Min: 0.05   Max: 14.34
Current: 0.42

0.05
14.34
Quick Ratio 0.42
GNBT's Quick Ratio is ranked lower than
66% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. GNBT: 0.42 )
GNBT' s 10-Year Quick Ratio Range
Min: 0.05   Max: 14.34
Current: 0.42

0.05
14.34

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) -38.20
GNBT's Earnings Yield (Greenblatt) is ranked lower than
69% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -6.40 vs. GNBT: -38.20 )
GNBT' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -38.2

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Generex Biotechnology Corp. was incorporated in Delaware in September 1997. The Company is engaged in the research, development and commercialization of drug delivery systems and technologies. Its focus at the present time is its proprietary technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a hand-held aerosol applicator. Through its wholly-owned subsidiary, Antigen, the Company has expanded its focus to include immunomedicines incorporating proprietary vaccine formulations. The Company's buccal delivery technology is a platform technology that has application to many large molecule drugs and provides a convenient, non-invasive, accurate and cost-effective way to administer such drugs. It has identified several large molecule drugs as possible candidates for development, including estrogen, heparin, monoclonal antibodies, human growth hormone and fertility hormone, but to date has focused its development efforts on one pharmaceutical product, Generex Oral-lyn, an insulin formulation administered as a fine spray into the oral cavity using its proprietary hand-held aerosol spray applicator known as RapidMist. The Company has received a Special Access Program (SAP) authorization from Health Canada for a patient-specific, physician-supervised treatment of Type-1 diabetes with Generex Oral-lyn in April 2008. In November 2008 the Company, together with its marketing partner Shreya Life Sciences Pvt. Ltd., officially launched Generex Oral-lyn in India under marketing name of Oral Recosulin. Using its buccal delivery technology, it also has launched a line of over-the-counter glucose and energy sprays , including Glucose RapidSpray(tm), Crave-NX(tm) 7-day Diet Aid Spray, and BaBOOM! Energy Spray. The Company's products would complement Generex Oral-lyn and might provide with an additional revenue stream prior to the commercialization of Generex Oral-lyn(tm) in other major jurisdictions. It received modest revenues from sales of its commercially available products, its confectionary, Glucose RapidSpray, a flavored glucose 'energy' spray supplemented with vitamins, BaBOOM! Energy Spray, and a fat-free glucose spray to aid in dieting, Crave-NX. All three products are available in retail stores and independent pharmacies in the United States and Canada. The Company's goal is to develop and commercialize its buccal delivery technology to administer large molecule drugs, including insulin, and proprietary vaccine formulations based upon two Antigen platform technologies to provide innovative biopharmaceutical products that offer the potential for efficacy and safety over existing products. The Company's faces competition from other providers of alternate forms of insulin. Some of its competitors include, Pfizer, Eli Lilly, and Novo Nordisk, have announced that they would discontinue development and/or sale of its inhalable forms of insulin.
» More Articles for GNBT

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: TDG, GNBT, ADGE, HFC, AMSWA Jul 02 2012 
Weekly CFO Buys Highlight: FCTOA, GNBT, CTTC, ELGX, ARTC Nov 06 2010 
Weekly CFO Buys Highlight: GNBT, CTTC, COIN, AUMN, SOMH Oct 31 2010 
Weekly CFO Buys Highlight: Information Services Group Inc., BioFuel Energy Corp., Oculus Innovative Nov 22 2009 
Generex Biotechnology Corp. (GNBT) CEO Anna E Gluskin buys 10,000 Shares Nov 16 2009 
Generex Biotechnology Corp. (GNBT) CFO Rose C Perri buys 10,000 Shares Nov 16 2009 
Generex Biotechnology Corp. (GNBT) Files Quarterly Report for the Period Ended on 2008-10-31 Dec 15 2008 

More From Other Websites
Generex Announces Collaboration on Medicinal Cannabis Nov 18 2014
Generex Announces Collaboration on Medicinal Cannabis Nov 18 2014
Generex Announces Presentation at the Society for Immunotherapy of Cancer Demonstrating that... Nov 11 2014
Generex Announces Presentation at the Society for Immunotherapy of Cancer Demonstrating that... Nov 11 2014
OTC Markets Group Welcomes Generex Biotechnology to OTCQB Nov 11 2014
Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase... Oct 27 2014
Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase... Oct 27 2014
Generex / Antigen Express to Participate in 2014 BIO-Europe® Annual International Partnering... Oct 23 2014
Generex / Antigen Express to Participate in 2014 BIO-Europe® Annual International Partnering... Oct 23 2014
Generex Announces Publication of Ebola Vaccine White Paper by Antigen Express Oct 21 2014
Generex Announces Publication of Ebola Vaccine White Paper by Antigen Express Oct 21 2014
GENEREX BIOTECHNOLOGY CORP Financials Oct 10 2014
Generex Clarifies Utility of Antigen Express Technology for Potential Ebola Vaccine Oct 07 2014
10-K for Generex Biotechnology Corp. Oct 05 2014
GENEREX BIOTECHNOLOGY CORP Files SEC form 10-K, Annual Report Oct 03 2014
Generex Announces Engagement of Dr. Lakshmi P. Kotra for Buccal Insulin Enhancement Project Sep 30 2014
Generex Collaborates with University Health Network for Buccal Insulin Project Sep 22 2014
Generex / Antigen Express to Participate in BioPharm America™ 2014 Sep 03 2014
Generex Announces Publication of AE37 Prostate Cancer Vaccine Study Aug 06 2014
Generex Announces Interview of Dr. Eric von Hofe, President of Antigen Express, Following Recent... Jun 17 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK